Safety and Reactogenicity of 2 Doses of SARS-CoV-2 Vaccination in Solid Organ Transplant Recipients
Michael T. Ou(Johns Hopkins University), Jacqueline Garonzik‐Wang(University of Wisconsin–Madison), Allan B. Massie(Johns Hopkins University), Dorry L. Segev(New York University), Jennifer D. Motter(Johns Hopkins University), Jake A. Ruddy(Johns Hopkins University), William A. Werbel(Johns Hopkins University), Vedant Jain(Johns Hopkins University), Michelle R. Krach(Johns Hopkins University), Ross S. Greenberg(Johns Hopkins University), Aura T. Teles(Johns Hopkins University), Brian J. Boyarsky(Johns Hopkins University), Robin K. Avery(Johns Hopkins University)
Cited by 88
Related Papers
Foot strike patterns and collision forces in habitually barefoot versus shod runners
|Nature|2010|1.4k
The Banff 2017 Kidney Meeting Report: Revised diagnostic criteria for chronic active T cell–mediated rejection, antibody-mediated rejection, and prospects for integrative endpoints for next-generation clinical trials
|American Journal of Transplantation|2017|1k
Antibody Response to 2-Dose SARS-CoV-2 mRNA Vaccine Series in Solid Organ Transplant Recipients
|JAMA|2021|1k
Immunogenicity of a Single Dose of SARS-CoV-2 Messenger RNA Vaccine in Solid Organ Transplant Recipients
|JAMA|2021|536
Kidney-Failure Risk Projection for the Living Kidney-Donor Candidate
|New England Journal of Medicine|2015|450